AMN Healthcare Services, Inc. (AMN – Free Report) is well-poised for growth, backed by its wide range of services and strong performance across segments in the first quarter of 2022.
Shares of this Zacks Rank #1 (Strong Buy) stock have gained 10.7% against the industry’s decline of 51.5% in a year’s time. The S&P 500 Index has fallen 12% in the same time frame.
AMN — with a market capitalization of $4.68 billion — is a travel healthcare staffing company. The company projects 1.1% growth for the next five years and expects to witness continued improvements in its business. AMN Healthcare surpassed the Zacks Consensus Estimate in each of the trailing four quarters, the average surprise being 15.6%.
What’s Driving the Performance?
AMN Healthcare’s business has evolved beyond traditional healthcare staffing. The company has become a strategic total talent solutions partner with its clients. AMN Healthcare has expanded its portfolio to serve a diverse and growing set of healthcare talent-related needs. The company enables clients to build and optimize their healthcare talent to deliver great patient outcomes and experience.
The company has been displaying strength in digital health capabilities with its AMN Passport and AMN Cares. The first one is the company’s mobile app for healthcare experts, while AMN Cares is a telehealth platform aiding care teams to interface with employees or patients at home.
Image Source: Zacks Investment Research
All three of AMN Healthcare’s reportable segments witnessed robust performances in the first quarter of 2022. The Nurse and Allied Solutions segment’s revenues surged 87% year over year. Travel nurse staffing revenues grew 95% year over year while Allied division revenues rose 64% year over year. The Physician and Leadership Solutions segment’s revenues were up 27.5% year over year. This upside can be attributed to a 30% growth in locum tenens revenues. Interim leadership revenues were up 14% year over year. Physician and leadership search businesses witnessed revenue growth of 46% year over year.
The Technology and Workforce Solutions segment’s revenues increased 63.8% year over year. Language services business revenues were up 20% year over year, while the vendor management systems (VMS) business improved a whopping 136% year over year.
For 2022, the Zacks Consensus Estimate for revenues is pegged at $5.02 billion, indicating an improvement of 25.9% from the year-ago period’s reported figure. The same for earnings stands at $10.46, suggestive growth of 30.3% from the prior-year quarter.
Other Stocks to Consider
Some other top-ranked stocks in the overall medical space are Omnicell, Inc. (OMCL – Free Report) , Masimo Corporation (MASI – Free Report) and ShockWave Medical, Inc. (SWAV – Free Report) .
Omnicell surpassed earnings estimates in three of the trailing four quarters and missed once, the average surprise being 13.4%. The company currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Omnicell’s long-term earnings growth rate is estimated at 20%. The company’s earnings yield of 3.4% compares favorably with the industry’s (11.7%).
Masimo beat earnings estimates in each of the trailing four quarters, the average surprise being 4.4%. The company currently carries a Zacks Rank #2.
Masimo’s estimated earnings growth rate for second-quarter 2022 is pegged at 22.3%. The company’s earnings yield is 3.8% against the industry’s (8.5%).
ShockWave Medical surpassed earnings estimates in each of the trailing four quarters, the average surprise being 189.9%. The company currently sports a Zacks Rank #1.
ShockWave Medical’s earnings growth rate for 2022 is estimated at 807.7%. The company’s earnings yield of 0.9% compares favorably with the industry’s (8%).